Fondazione Gianni Bonadonna
LightNews LightNews
banner
fgbonadonna.bsky.social
Fondazione Gianni Bonadonna
@fgbonadonna.bsky.social
92 followers 530 following 47 posts
FGB promotes therapeutic innovation from the earliest phases of research and the education of new generations of physician-scientists in Oncology
Posts Replies Media Videos
fgbonadonna.bsky.social
A lot of advances have emerged from the Joint International Conference 2025 Innovation in Oncology organized by FGB with Prada Group supporting partner, by Fondazione Michelangelo and by European School of Oncology
fondazionebonadonna.org/en/from-new-...
#FondazioneGianniBonadonna #CancerResearch
November 17, 2025 at 1:57 PM
fgbonadonna.bsky.social
The Godard Cinema of Fondazione Prada hosted today the opening press conference of the “Joint International Conference 2025”. The event is organized by FGB with the support of #PradaGroup #FondazioneMichelangelo and @ESOncology .
fondazionebonadonna.org/wp-content/u...
#CancerResearch #Oncology
November 12, 2025 at 4:58 PM
fgbonadonna.bsky.social
mRNA vaccines targeting non-tumor-related antigens are potent immune modulators capable of sensitizing tumors to immune checkpoint blockade
fondazionebonadonna.org/en/sars-cov-...
#FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social
SARS-CoV-2 vaccines sensitize tumors to immune checkpoint blockade
Fondazione Gianni Bonadonna
fondazionebonadonna.org
November 10, 2025 at 10:53 AM
fgbonadonna.bsky.social
Capivasertib added to abiraterone with androgen deprivation therapy increases progression-free survival in patients with PTEN-deficient metastatic hormone-sensitive prostate cancer
fondazionebonadonna.org/en/capivaser...

#FondazioneBonadonna #Oncology #CancerResearch

@mauriziocallari.bsky.social
Capivasertib plus abiraterone in metastatic hormone-sensitive prostate cancer
Fondazione Gianni Bonadonna
fondazionebonadonna.org
November 3, 2025 at 10:38 AM
fgbonadonna.bsky.social
Final overall survival data from SOLTI-1303-PATRICIA trial highlight the relevance of gene expression profiling in HER2+ breast cancer, validating the potential of non-chemotherapy approaches in selected patients
fondazionemichelangelo.org/it/notizie-e...
#FondazioneMichelangelo #CancerResearch
October 29, 2025 at 9:50 AM
fgbonadonna.bsky.social
Adding radiotherapy to immunotherapy can have systemic immunomodulatory and antitumor effects and may be a way to overcome immunotherapy resistance in non-small cell lung cancer
fondazionebonadonna.org/en/pembroliz...
#FondazioneBonadonna #Oncology
@mauriziocallari.bsky.social
Pembrolizumab and radiotherapy in immunologically cold non-small cell lung cancer
Fondazione Gianni Bonadonna
fondazionebonadonna.org
October 27, 2025 at 11:58 AM
fgbonadonna.bsky.social
A phase 2 study with the antibody-drug conjugate patritumab deruxtecan showed promising activity and manageable tolerability in patients with HR+/HER2− metastatic breast cancer
fondazionebonadonna.org/en/patrituma...
#FondazioneBonadonna #Oncology #CancerResearch
@mauriziocallari.bsky.social
Patritumab deruxtecan in HR+/HER2- advanced breast cancer
Fondazione Gianni Bonadonna
fondazionebonadonna.org
October 20, 2025 at 10:08 AM
fgbonadonna.bsky.social
Analysis of the NeoTRIP trial showed that tumor-specific MHC-II expression is associated with improved response to neoadjuvant chemo-immunotherapy in early triple negative breast cancer
fondazionemichelangelo.org/news-update/...
#FondazioneMichelangelo #CancerResearch
@mauriziocallari.bsky.social
October 15, 2025 at 8:18 AM
fgbonadonna.bsky.social
Precemtabart tocentecan, an anti-CEACAM5 antibody-drug conjugate, shows a predictable safety profile and a promising antitumor activity in metastatic colorectal cancer
fondazionebonadonna.org/en/the-antib...
#FondazioneBonadonna #Oncology #CancerResearch
@mauriziocallari.bsky.social
The antibody-drug conjugate precemtabart tocentecan in metastatic colorectal cancer
Fondazione Gianni Bonadonna
fondazionebonadonna.org
October 13, 2025 at 12:11 PM
fgbonadonna.bsky.social
Camizestrant in association with abemaciclib, palbociclib or ribociclib shows a well-tolerated safety profile and encouraging clinical activity in heavily pretreated advanced breast cancer
fondazionebonadonna.org/en/camizestr...
#Oncology #CancerResearch
@mauriziocallari.bsky.social
October 7, 2025 at 1:36 PM
fgbonadonna.bsky.social
Phost’in Therapeutics and Fondazione Gianni Bonadonna to present first clinical data on PhOx430, a First-In-Class GnT-V inhibitor, at @myesmo.bsky.social 2025. Press release fondazionebonadonna.org/wp-content/u...
#PhostInTherapeutics #FondazioneBonadonna #therapeuticinnovation #CancerResearch
October 3, 2025 at 8:08 AM
fgbonadonna.bsky.social
Respiratory viral infections can lead to loss of the pro-dormancy phenotype in disseminated #BreastCancer cells in the lung, causing proliferation and expansion of carcinoma cells within days
fondazionebonadonna.org/en/metastati...
#FondazioneBonadonna #Oncology
@mauriziocallari.bsky.social
Metastatic breast cancer cells awakened by lung infections
Fondazione Gianni Bonadonna
fondazionebonadonna.org
September 30, 2025 at 8:29 AM
fgbonadonna.bsky.social
The ATRACTIB phase 2 trial shows clinical benefit with a combination of atezolizumab, paclitaxel and bevacizumab as first-line treatment in advanced triple-negative breast cancer
fondazionebonadonna.org/en/atezolizu...
#FondazioneBonadonna #CancerResearch #Oncology @mauriziocallari.bsky.social
Atezolizumab, paclitaxel and bevacizumab as first line therapy in triple-negative breast cancer
Fondazione Gianni Bonadonna
fondazionebonadonna.org
September 22, 2025 at 8:55 AM
fgbonadonna.bsky.social
A dual HER2-targeted blockade with neoadjuvant pyrotinib and ARX788, a new antibody-drug conjugate, as a promising strategy in early or locally advanced HER2-positive breast cancer
fondazionebonadonna.org/en/pyrotinib...
#FondazioneBonadonna #CancerResearch #Oncology @mauriziocallari.bsky.social
Pyrotinib plus a new antibody-drug conjugate in HER+ breast cancer
Fondazione Gianni Bonadonna
fondazionebonadonna.org
September 15, 2025 at 8:14 AM
fgbonadonna.bsky.social
Milan to host the Joint Conference 2025 on New Drugs and the Impact of AI in Oncology, organized by FGB with the Prada Group as supporting partner, Fondazione Michelangelo and @ESOncology .
Press Release fondazionebonadonna.org/area-press/
#FondazioneGianniBonadonna #FondazioneMichelangelo
September 10, 2025 at 1:48 PM
fgbonadonna.bsky.social
SERENA-6 trial shows a longer progression-free survival with camizestrant added to a CDK4/6 inhibitor in advanced breast cancer with an ESR-1 mutation emerged during treatment fondazionemichelangelo.org/news-update/...
#FondazioneBonadonna #FondazioneMichelangelo #CancerResearch #Oncology
September 8, 2025 at 11:03 AM
fgbonadonna.bsky.social
MATTERHORN trial results show a significantly better event-free survival with perioperative durvalumab added to chemotherapy in resectable gastric or gastroesophageal junction adenocarcinoma
fondazionebonadonna.org/en/periopera...
#FondazioneBonadonna #CancerResearch @mauriziocallari.bsky.social
Perioperative durvalumab in gastric and gastroesophageal junction cancer
Fondazione Gianni Bonadonna
fondazionebonadonna.org
September 1, 2025 at 8:53 AM
fgbonadonna.bsky.social
Final results from the IMpassion031 trial confirm that adding atezolizumab to neoadjuvant chemotherapy significantly improved clinical outcomes and cleared ctDNA at surgery
fondazionemichelangelo.org/news-update/...
#FondazioneMichelangelo #CancerResearch #Oncology
Peri-operative atezolizumab in early-stage triple-negative breast cancer - Fondazione Michelangelo
Final results from the IMpassion031 trial confirm that adding atezolizumab to neoadjuvant chemotherapy significantly improved clinical outcomes and cleared ctDNA at surgery
fondazionemichelangelo.org
August 27, 2025 at 8:53 AM
fgbonadonna.bsky.social
A phase 3 study shows clinical benefit for tarlatamab as second-line treatment after chemotherapy in patients with small-cell lung cancer
fondazionebonadonna.org/en/longer-su...
#fondazionemichelangelo #oncology #CancerResearch
@mauriziocallari.bsky.social
Longer survival with tarlatamab in small-cell lung cancer
Fondazione Gianni Bonadonna
fondazionebonadonna.org
August 25, 2025 at 9:27 AM
fgbonadonna.bsky.social
In ER-positive, HER2-negative advanced breast cancer vepdegestrant led to significantly longer progression-free survival than fulvestrant in the subgroup with ESR1 mutations
www.fondazionemichelangelo.org/news-update/...
#fondazionemichelangelo #oncology #CancerResearch
The PROTAC estrogen receptor degrader vepdegestrant in advanced breast cancer - Fondazione Michelangelo
In ER-positive, HER2-negative advanced breast cancer vepdegestrant led to significantly longer progression-free survival than fulvestrant in the subgroup with ESR1 mutations
www.fondazionemichelangelo.org
August 6, 2025 at 10:35 AM
fgbonadonna.bsky.social
Trastuzumab deruxtecan led to significantly longer overall survival than ramucirumab plus paclitaxel among patients with HER2-positive metastatic gastric cancer or gastroesophageal junction adenocarcinoma
fondazionebonadonna.org/en/trastuzum...
#FondazioneBonadonna #Oncology #CancerResearch
Trastuzumab deruxtecan or ramucirumab plus paclitaxel in gastric cancer
Fondazione Gianni Bonadonna
fondazionebonadonna.org
August 4, 2025 at 9:18 AM
fgbonadonna.bsky.social
“Online the Scientific Programme of the FGB-FM-ESO Joint International Conference 2025 “INNOVATION IN ONCOLOGY: New Drugs and the Impact of Artificial Intelligence”. Read more and register online at www.eso.net/en/what-we-d...
July 30, 2025 at 9:55 AM
fgbonadonna.bsky.social
Adjuvant cemiplimab led to to longer disease-free survival than placebo in cutaneous squamous-cell carcinoma with a high risk for recurrence
fondazionebonadonna.org/en/cemiplima...

#FondazioneBonadonna #Oncology #CancerResearch

@mauriziocallari.bsky.social
Cemiplimab in high risk cutaneous squamous-cell carcinoma
Fondazione Gianni Bonadonna
fondazionebonadonna.org
July 29, 2025 at 8:34 AM
fgbonadonna.bsky.social
Addition of pembrolizumab to enzalutamide and androgen deprivation therapy is not effective in metastatic hormone-sensitive prostate cancer
fondazionebonadonna.org/en/pembroliz...
#FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social
Pembrolizumab plus enzalutamide and androgen deprivation therapy in prostate cancer
Fondazione Gianni Bonadonna
fondazionebonadonna.org
July 22, 2025 at 8:26 AM
fgbonadonna.bsky.social
Sunday July 20th is the deadline for submitting applications for the “Fellowship Gianni Bonadonna” ed 25 – Read more fondazionebonadonna.org/en/fellowshi...

Il 20 luglio scadono i termini per inviare la candidature per la “Fellowship Gianni Bonadonna” 25 - Leggi fondazionebonadonna.org/fellowship/
July 16, 2025 at 8:39 AM